Vericel Corporation (NASDAQ:VCEL) Receives $60.40 Consensus Target Price from Analysts

Key Points

• Vericel Corporation (NASDAQ:VCEL) has received an average rating of "Buy" from five brokerage firms, with a consensus price target of $60.40 for the next year.
• Despite a recent 4.0% decline in share price, Vericel's stock has fluctuated between $30.26 and $63.00 over the past twelve months, reflecting significant market interest.
• The company reported a 20.1% year-over-year revenue growth with earnings per share of ($0.01), surpassing analysts' expectations for the most recent quarter.

Vericel Corporation (NASDAQ:VCEL - Get Free Report) has earned a consensus rating of "Moderate Buy" from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $60.40.

VCEL has been the topic of several analyst reports. Canaccord Genuity Group cut their target price on Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a research note on Friday, August 1st. BTIG Research lowered Vericel from a "buy" rating to a "neutral" rating in a research note on Wednesday. Finally, Stephens reissued an "overweight" rating and issued a $67.00 target price on shares of Vericel in a research note on Monday, June 16th.

Hedge Funds Weigh In On Vericel

Institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its position in shares of Vericel by 119.3% during the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock worth $70,775,000 after buying an additional 701,064 shares during the period. Allspring Global Investments Holdings LLC raised its position in Vericel by 244.6% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 859,486 shares of the biotechnology company's stock valued at $35,755,000 after buying an additional 610,045 shares during the last quarter. Geneva Capital Management LLC raised its position in Vericel by 30.7% in the 2nd quarter. Geneva Capital Management LLC now owns 1,784,927 shares of the biotechnology company's stock valued at $75,949,000 after buying an additional 419,183 shares during the last quarter. Conestoga Capital Advisors LLC raised its position in Vericel by 19.5% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 2,463,590 shares of the biotechnology company's stock valued at $104,826,000 after buying an additional 401,990 shares during the last quarter. Finally, Champlain Investment Partners LLC raised its position in Vericel by 62.5% in the 2nd quarter. Champlain Investment Partners LLC now owns 997,291 shares of the biotechnology company's stock valued at $42,435,000 after buying an additional 383,498 shares during the last quarter.

Vericel Stock Up 0.2%

VCEL stock traded up $0.05 during midday trading on Monday, reaching $31.90. The stock had a trading volume of 270,862 shares, compared to its average volume of 538,735. The business has a fifty day simple moving average of $35.98 and a two-hundred day simple moving average of $40.42. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of 265.81 and a beta of 1.33. Vericel has a twelve month low of $29.93 and a twelve month high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. The firm had revenue of $63.24 million during the quarter, compared to analyst estimates of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company's revenue was up 20.1% on a year-over-year basis. During the same period last year, the company earned ($0.10) earnings per share. On average, equities analysts predict that Vericel will post 0.14 earnings per share for the current fiscal year.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.